MacroGenics Dirección

Dirección controles de criterios 3/4

El CEO de MacroGenics' es Scott Koenig , nombrado en Sep 2001, tiene una permanencia de 22.58 años. compensación anual total es $3.71M, compuesta por 19% salario y 81% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.08% de las acciones de la empresa, por valor de €19.01M. La antigüedad media del equipo directivo y de la junta directiva es de 7.2 años y 6.8 años, respectivamente.

Información clave

Scott Koenig

Chief Executive Officer (CEO)

US$3.7m

Compensación total

Porcentaje del salario del CEO	19.0%
Permanencia del CEO	22.8yrs
Participación del CEO	2.1%
Permanencia media de la dirección	7.4yrs
Promedio de permanencia en la Junta Directiva	7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Scott Koenig en comparación con los beneficios de MacroGenics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$4m	US$705k	-US$9m
Sep 30 2023	n/a	n/a	US$50m
Jun 30 2023	n/a	n/a	US$7m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$5m	US$673k	-US$120m
Sep 30 2022	n/a	n/a	-US$191m
Jun 30 2022	n/a	n/a	-US$219m
Mar 31 2022	n/a	n/a	-US$217m
Dec 31 2021	US$5m	US$651k	-US$202m
Sep 30 2021	n/a	n/a	-US$146m
Jun 30 2021	n/a	n/a	-US$129m
Mar 31 2021	n/a	n/a	-US$136m
Dec 31 2020	US$3m	US$656k	-US$130m
Sep 30 2020	n/a	n/a	-US$158m
Jun 30 2020	n/a	n/a	-US$167m
Mar 31 2020	n/a	n/a	-US$152m
Dec 31 2019	US$5m	US$590k	-US$152m
Sep 30 2019	n/a	n/a	-US$166m
Jun 30 2019	n/a	n/a	-US$155m
Mar 31 2019	n/a	n/a	-US$167m
Dec 31 2018	US$5m	US$599k	-US$171m
Sep 30 2018	n/a	n/a	-US$21m
Jun 30 2018	n/a	n/a	-US$34m
Mar 31 2018	n/a	n/a	-US$32m
Dec 31 2017	US$3m	US$554k	-US$20m

Compensación vs. Mercado: La compensación total de Scott($USD3.71M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.29M).

Compensación vs. Ingresos: La compensación de Scott ha sido consistente con los resultados de la empresa en el último año.

CEO

Scott Koenig (72 yo)

22.8yrs

Permanencia

US$3,705,825

Compensación

Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Scott Koenig	President	22.8yrs	US$3.71m	2.07% $ 5.4m
James Karrels	Senior VP	16.1yrs	US$1.58m	0.27% $ 719.1k
Stephen Eck	Senior VP of Clinical Development & Chief Medical Officer	3.9yrs	US$1.75m	0.016% $ 41.1k
Eric Risser	Chief Operating Officer	2.3yrs	US$1.92m	0.062% $ 163.1k
Thomas Spitznagel	Senior Vice President of Technical Operations	1.6yrs	US$1.88m	0.013% $ 34.9k
Ezio Bonvini	Senior VP of Research & Chief Scientific Officer	7.8yrs	US$2.29m	0.16% $ 423.1k
Jeffrey Peters	Senior VP	7yrs	sin datos	0% $ 0
Lynn Cilinski	VP, Controller & Treasurer	20.7yrs	sin datos	0.0099% $ 26.1k

7.4yrs

Permanencia media

61.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de M55 es experimentado (7.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Scott Koenig	President	22.8yrs	US$3.71m	2.07% $ 5.4m
David Stump	Independent Director	10.8yrs	US$160.75k	0.0072% $ 18.9k
Federica O'Brien	Independent Director	3.3yrs	US$152.00k	0.0072% $ 18.9k
Edward Hurwitz	Independent Director	19.7yrs	US$147.63k	0.060% $ 157.6k
Margaret Liu	Independent Director	1.4yrs	US$318.32k	0.0072% $ 18.9k
William Heiden	Independent Chairman of the Board	2.1yrs	US$180.13k	0.0072% $ 18.9k
Meenu Chhabra Karson	Independent Director	1.4yrs	US$335.41k	0.0072% $ 18.9k
Scott Jackson	Independent Director	7.4yrs	US$167.63k	0.0072% $ 18.9k
Jay Siegel	Independent Director	6.6yrs	US$167.21k	0.0072% $ 18.9k
Karen Jean Ferrante	Independent Director	7.4yrs	US$135.75k	0.0072% $ 18.9k

7.0yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de M55 se considera experimentada (6.8 años de antigüedad promedio).

MacroGenics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insider recently bought €67k worth of stock

MacroGenics, Inc. Appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

Macrogenics, Inc. Approves the Appointment of Margaret Liu, M.D. to Serve as Director

Senior VP recently bought €95k worth of stock

MacroGenics, Inc. Announces Management Changes

Insufficient new directors

Recent updates

First quarter 2024 earnings released: US$0.84 loss per share (vs US$0.61 loss in 1Q 2023)

MacroGenics, Inc. Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

Full year 2023 earnings released: US$0.15 loss per share (vs US$1.95 loss in FY 2022)

Investor sentiment improves as stock rises 15%

MacroGenics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 21%

Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.40 loss in 3Q 2022)

MacroGenics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Insider recently bought €67k worth of stock

Investor sentiment deteriorates as stock falls 16%

New major risk - Share price stability

Second quarter 2023 earnings released: EPS: US$0.93 (vs US$0.67 loss in 2Q 2022)

MacroGenics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: US$0.61 loss per share (vs US$1.08 loss in 1Q 2022)

MacroGenics, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: US$1.95 loss per share (vs US$3.37 loss in FY 2021)

Macrogenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients

MacroGenics, Inc. Appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

Macrogenics, Inc. Approves the Appointment of Margaret Liu, M.D. to Serve as Director

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.86 loss in 3Q 2021)

MacroGenics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.67 loss per share (vs US$0.67 loss in 2Q 2021)

MacroGenics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

MacroGenics, Inc. Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer

Senior VP recently bought €95k worth of stock

MacroGenics, Inc. Announces Management Changes

First quarter 2022 earnings released: US$1.08 loss per share (vs US$0.90 loss in 1Q 2021)

Insufficient new directors

MacroGenics, Inc. to Report Q1, 2022 Results on May 03, 2022

MacroGenics, Inc., Annual General Meeting, May 19, 2022

MacroGenics, Inc. Announces Promotion of Eric Risser to Chief Operating Officer

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

MacroGenics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: US$0.86 loss per share (vs US$0.66 loss in 3Q 2020)

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA in Patients with HER2-Positive Metastatic Breast Cancer

Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.94 loss in 2Q 2020)

Insufficient new directors

MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting

First quarter 2021 earnings released: US$0.90 loss per share (vs US$0.91 loss in 1Q 2020)

Full year 2020 earnings released: US$2.47 loss per share (vs US$3.16 loss in FY 2019)

Revenue beats expectations

MacroGenics, Inc. Provides Update Proprietary Programs

New 90-day low: €16.00

MacroGenics, Inc. to Report Q4, 2020 Results on Feb 25, 2021

MacroGenics, Inc. Names Federica O’Brien to its Board of Directors

New 90-day low: €16.30

Macrogenics, Inc. Announces the Publication of Results from the Sophia Trial of Margenza

Macrogenics, Inc. Announces Research Collaboration and Global License Agreement to Develop Preclinical Bispecific Molecule with Janssen Biotech, Inc

MacroGenics, Inc. Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia At the 2020 ASH Annual Meeting

MacroGenics, Inc. and EVERSANA Announces Agreement to Support the Potential Launch and Commercialization of Margetuximab

Revenue beats expectations

Third quarter 2020 earnings released: US$0.66 loss per share

MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020

MacroGenics, Inc. to Report Q3, 2020 Results on Nov 04, 2020

MacroGenics, Inc. Enters into A Commercial Supply Agreement with Incyte Corporation

MacroGenics Announces Flotetuzumab Publication in Blood Advances

New 90-day low: €20.80

New 90-day low: €21.00

MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood

MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte

MacroGenics, Inc. Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020

MacroGenics, Inc. announced that it has received funding from Havencrest Capital Management, LLC

MacroGenics, Inc. to Report Q2, 2020 Results on Jul 30, 2020

MacroGenics, Inc.(NasdaqGS:MGNX) dropped from Russell Microcap Index

MacroGenics, Inc.(NasdaqGS:MGNX) dropped from Russell Microcap Value Index